Plain-English translation of NCT04951817 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a newer type of imaging scan called 68Ga-PSMA PET/CT is better than traditional bone scans at detecting spread of advanced prostate cancer. Researchers want to compare how well these two imaging methods work in men who are receiving 223Ra-dichloride, a treatment that targets cancer in the bones. By comparing the results, doctors hope to improve how they monitor and treat this type of cancer.
Men with advanced prostate cancer that has spread to their bones need accurate imaging to track how well their treatment is working. Doctors want to know if the newer imaging scan can detect cancer progression better than the older method, which could help them make better treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will receive an intravenous injection of a radioactive tracer (68Ga-PSMA-11) and then have a PET/CT scan about 60 minutes later—this is a painless imaging procedure where you lie still inside a scanner. You will also have a traditional bone scan. Both scans are performed to help doctors compare which imaging method better shows any spread of your cancer while you are receiving your 223Ra-dichloride treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Taiwan
Sponsor
Chang Gung Memorial Hospital
Enrollment target
~52 participants
Started
March 2022
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
40 Years – 85 Years
Sex
Male only
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jing-Ren Tseng, MD
Chang Gung Memorial Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.